Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services

Stockhouse May 21 06:00

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke...

Stockhouse Apr 24 06:47

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch,...

Stockhouse Apr 11 06:00

Algernon Pharmaceuticals to Move Forward With Psychedelic Drug DMT Stroke Research Program as Its...

Stockhouse Apr 1 06:00

Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company

Algernon Pharmaceuticals Inc. (AGN.CN) announced that Seyltx Inc., a privately owned U.S. based drug development company, has closed on its acquisition of Algernon's NP-120 (Ifenprodil) research progr

MT NewswiresMar 27 12:02

Press Release: Algernon Pharmaceuticals Announces Closing of the Acquisition of Its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position VANCOUVER, British Columbia, March 27, 2

Dow JonesMar 27 11:04